HOME >> BIOLOGY >> NEWS
UT Southwestern researchers find gene mutation that leads to 'broken hearts'

Dallas -- July 20, 2006 -- Researchers at UT Southwestern Medical Center have identified a group of fruit fly gene mutations responsible for "broken hearts" in the embryonic stages of development, a discovery that could help identify genes that cause human heart defects.

"We engineered a fruit fly so that the heart would glow in the dark and found a new type of malformation, completely unexpectedly," said Dr. Eric Olson, chairman of molecular biology at UT Southwestern and senior author of the study appearing in today's issue of Science. "We coined the term 'brokenhearted' for this defect because two kinds of cardiac cells separated, thus causing the heart to fall apart, with a loss of heart function and embryonic death."

The heart is the first organ to form and function in the embryo. Abnormalities in the complex process of heart formation result in congenital heart defects, the most common birth defects in humans afflicting about 1 percent of newborns. Because the events of heart formation are very similar throughout the animal world, the fruit fly is a useful model to study the causes of heart defects in mammals, Dr. Olson said.

The researchers found that mutations in genes encoding enzymes in a pathway for synthesis of a small lipid caused this broken heart defect in fruit flies. One of these enzymes, HMG CoA reductase, also plays a key role in the synthesis of cholesterol in humans. In fruit flies, these enzymes are required to generate a small lipid to modify a signaling protein, which is required for heart formation. The study suggests the involvement of the same biochemical pathway in human heart formation and congenital heart disease.

"We were surprised to discover that a group of enzymes involved in lipid synthesis plays a previously unrecognized role in assembling the heart. The same mechanism is likely to be involved in human-heart development," said Dr. Olson, director of the Nancy B. and Jake L. Hamo
'"/>

Contact: Katherine Morales
katherine.morales@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
20-Jul-2006


Page: 1 2

Related biology news :

1. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
2. UT Southwestern leaders to receive national award for medical research accomplishments
3. UT Southwestern scientist receives NIH Directors Pioneer Award
4. UT Southwestern scientist named Keck Foundation Distinguished Young Scholar in Medical Research
5. Plague agent helps UT Southwestern researchers find novel signaling system in cells
6. One of the nations first 7-Tesla magnetic resonance imaging devices for human studies planned at UT Southwestern Medical Center
7. DNA end caps may lead to cancer treatments, UT Southwestern researchers report
8. UT Southwestern scientist honored among best in Texas research
9. UT Southwestern scientist receives international award for pediatric research
10. UT Southwestern physician-researcher wins international award for lipid research
11. UT Southwestern scientist elected to National Academy of Sciences Institute of Medicine

Post Your Comments:
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: